Table 2.
Multivariate Analyses for TTP and OS According to CHFR Status
| TTP |
OS |
||||
|---|---|---|---|---|---|
| Covariates in the Final Model | Adjusted HR (95% CI) | P | Covariates in the Final Model | Adjusted HR (95% CI) | P |
| CHFR unmethylated | 2.88 (1.50-5.52) | .001 | CEA >5.0 ng/ml | 2.33 (1.42-3.80) | .01 |
| No. prior treatments | <.001 | No. prior treatments | .002 | ||
| 1 | 2.78 (1.60-4.86) | <.001 | 1 | 2.78 (1.60-4.86) | <.001 |
| ≥2 | 3.43 (1.69-6.97) | <.001 | ≥2 | 3.43 (1.69-6.97) | <.001 |
| hMLH/hMSH2 deficient | 4.49 (1.02-19.66) | .046 | |||
| Metastatic organs ≥3 | 2.28 (1.19-4.37) | .013 | |||
Multivariate analyses were performed by Cox regression analysis with forward conditional selection method adjusted for age (continuous), sex, differentiation (well to moderately differentiated vs. poorly differentiated), tumor location (right vs. left), metastatic organs (1-2 vs. ≥3), CEA level (≤5 vs. >5.0 ng/ml), BRAF mutation, hMLH1/hMSH2, number of prior treatment(s), promoter methylation, and CIMP status.